[Cell Adhesion & Migration 1:2, 56-61; April June 2007]; ©2007 Landes Bioscience



Review

Neuropilins
Novel Targets Anti-Angiogenesis Therapies


Elena Geretti1                                                                  Abstract
Michael Klagsbrun1,2,*                                                             established neuropilins (NRP1 NRP2), described ­mediators
                                                                                neuronal guidance, mediators angiogenesis tumor ­progression. NRPs
1Department  Surgery;   2Departmentof Pathology; Vascular Biology Program;
                                                                                receptors class‑3 semaphorin (SEMA) family axon guidance molecules
Children’s Hospital Harvard Medical School; Boston, Massachusetts USA
                                                                                vascular endothelial growth factor (VEGF) family angiogenic factors.
*Correspondence  Michael Klagsbrun; Vascular Biology Program; Children’s     VEGF‑NRP interactions promote developmental angiogenesis shown mouse
Hospital, Boston; Karp Building 12210; 300 Longwood Avenue; Boston,
                                                                                knockout zebrafish knockdown studies. evidence NRPs mediate
Massachusetts 02115 USA; Tel.: 617.919.2157; Fax: 617.730.0233; Email:
michael.klagsbrun@childrens.harvard.edu                                         tumor progression. example, overexpression NRP1 enhances tumor growth
                                                                                NRP1 antagonists, soluble NRP1 anti‑NRP1 antibodies, inhibit
Original manuscript submitted: 05/07/07
                                                                                tumor growth. Furthermore, class‑3 SEMAs acting NRPs inhibit tumor angiogen-
Manuscript accepted: 05/25/07
                                                                                esis, progression metastasis. Clinical data suggest high NRP levels correlate Previously published online Cell Adhesion & Migration E-publication:       poor prognosis survival variety cancer types. Taken  results
http://www.landesbioscience.com/journals/celladhesion/article/4490
                                                                                suggest NRPs potentially valuable targets new anti‑cancer ­ therapies.                                                                                 analyze current knowledge NRPs role ­angiogenesis tumor
Keywords                                                                        progression enumerate strategies targeting receptors.
neuropilin, semaphorin, VEGF, angiogenesis,
axon guidance, cancer, metastasis
                                                                                Neuropilin Background
Abbreviations
                                                                                       Anti‑VEGF antibodies received attention lately ability block
NRP	                 neuropilin
                                                                                tumor angiogenesis prolong life cancer patients.1 2004, Bevacizumab
SEMA	                semaphorin
                                                                                (Avastin), humanized monoclonal antibody VEGF  VEGF	                vascular endothelial growth factor
                                                                                ­antiangiogenic drug approved FDA line treatment metastatic colorectal
VEGFR	               VEGF receptor
                                                                                 cancer ­combination chemotherapy. anti‑VEGF antibody, Ranibizumab
EC	                  endothelial cell
                                                                                 (Lucentis), monoclonal antibody Fab, successful treatment PAE cells	           porcine aortic endothelial cells
                                                                                 ­neovascularization associated wet neovascular age‑related macular degeneration
ISV	                 intersegmental vessels
                                                                                  (AMD), ­ alleviating blindness patients.2  cancer patients DRG	                 dorsal root ganglia
                                                                                  anti‑VEGF‑chemotherapy combination adverse effects including hypertension,
                                                                                  impaired wound healing arterial thrombotic events.3  promising ­development
Acknowledgments
                                                                                  surfaced recently article Pan et al.4 reported antibodies thank Drs. Dhara Amin, Silvia Coma                                             ­neuropilin‑1 (NRP1) combination anti‑VEGF enhanced ability anti‑VEGF Kashi Javaherian critical ­evaluation                                   block tumor growth. manuscript. thank Melissa Herman                                                NRPs, NRP1 NRP2. NRPs single pass ­transmembrane proofreading manuscript Kristin                                        glycoproteins. NRPs discovered expressed neurons.5 Subsequently,
Johnson technical assistance figure                                         NRP1 identified receptor semaphorin 3A (SEMA3A), mediator axon
­preparation. work supported                                           guidance repels axons collapses growth cones.6 Surprisingly, NRPs  National Institute Health NCI grants                                           soon receptors VEGF family angiogenesis factors, suggesting  CA37392 CA45548  Michael                                                   receptor involved blood vessel formation.7 Structurally, NRPs large
 Klagsbrun).                                                                       extracellular domain (~840 amino acid residues) containing  B C ­subdomains,
                                                                                   short transmembrane domain (~25 residues) ~40 residue long ­ cytoplasmic
                                                                                   sequence (Fig. 1). VEGF165 binds B domain, class‑3 SEMAs bind                                                                                    B domains.8‑10 VEGF modular protein consisting exons,                                                                                    differential splicing gives rise different isoforms. Importantly, exon 4 binds high
                                                                                   affinity VEGFR‑2 tyrosine kinase receptor, exons 7 8 bind NRPs
                                                                                   (Fig. 2A).  VEGF165 bind simultaneously receptors, VEGFR‑2                                                                                    NRP. VEGF165 stimulates enhanced chemotaxis EC express VEGFR‑2 NRP1
                                                                                   compared EC expressing VEGFR‑2 7 NRPs signaling motifs,
                                                                                   suggested NRP1 coreceptor VEGFR‑2.



56	                                                                                   Cell Adhesion & Migration	                                          2007; Vol. 1 Issue 2
                                                                   Neuropilins Angiogenesis


                                                                                 embryonic‑lethal displayed vascular defects including excess
                                                                                 numbers blood vessels, dilated blood vessels, hemorrhage,                                                                                  malformed hearts limbs.19 Nrp‑1‑deficient mice died utero                                                                                  E12.5 E13.5 exhibited vascular defects including abnormal
                                                                                 yolk sacs, abnormal neuronal vascularization, disorganized blood
                                                                                 vessels, lack normal branching, missing capillary networks,
                                                                                 cardiovascular defects including agenesis bronchial arches,
                                                                                 defects dorsal aorta, ­ transposition aortic arches.20
                                                                                  Nrp2‑deficient mice viable,21 developed arteries veins
Figure 1. Schematic representation NRP domain structure. sites        normally displayed severe ­reduction small lymphatic vessels interaction respective extracellular ligands, VEGF165 class‑3    ­ capillaries.16 Double Nrp1/Nrp2 knockout mice died E8.5
SEMAs, intracellular binding partner, Neuropilin Interacting      severe vascular ­ phenotype Nrp1‑deficient mice
Protein (NIP), shown.                                                        including avascular yolk sacs, growth ­ retardation lack vessel
                                                                                 development, ­capillary ­formation, branching.22
    anti‑VEGF combined anti‑NRP1 effective                           zebrafish, knockdown NRP1 antisense morpholinos tumor growth ­ inhibitor anti‑VEGF  Presumably,                  (MO) resulted vascular defects.23 defects included loss
VEGF165 exon 4 interactions VEGFR‑2 VEGF165 exons                       circulation intersegmental vessels (ISV), dorsal
7/8 interactions NRPs constitute different signaling pathways               ­longitudinal anastomotic vessels (DLAV), caudal vein different targets. evidence NRP signaling             plexus. ISV correspond angiogenic sprouts. Furthermore, independent VEGFR‑2, binding NRP interacting                      abnormal direct connections artery vein resembling
protein (NIP), PDZ domain‑containing protein.11 NIP identical                fistulas resulted aberrant return blood circulation RGS‑GAIP‑ interacting protein (GIPC), suggested                 heart.  MO treatment 1–4 cell stage did inhibit involved vesicular trafficking.12 GIPC interacts                axial vessel formation.  zebrafish, NRP1 regulator NRP1 C‑terminal residues, SEA‑COOH. zebrafish, GIPC knock-                     angiogenesis vasculogenesis. morpholinos resulted vascular defect resembling
NRP1 knockdown.11 NIP Synectin, required                 Neuropilins Semaphorins
arterial branching independent VEGF/VEGFR‑2.13,14
    study Pan et al. properties anti‑NRP                         set ligands NRPs class‑3 family ­antibodies investigated, anti‑NRP1A anti‑NRP1B, directed               s­ emaphorins (SEMA), seven members  G).
 NRP1 B domains, respectively. anti‑NRP1                    SEMAs described negative mediators axon ­pathfinding
 antibodies inhibited VEGF165‑induced EC migration, EC sprouting                  repel axons collapse growth cones.6,24 Surprisingly, turned
 neovascularization corneal pocket assay did                   semaphorins angiogenesis inhibitors   inhibit VEGF165‑induced VEGFR‑2 phosphorylation downstream                    SEMA‑NRP complex does transmit signals. Instead, NRPs
 signaling, EC proliferation, vascular permeability. Anti‑NRP1B                form complexes plexins, ­transmembrane proteins  effective, consistent B domain VEGF165               act substrates kinases, transduce SEMA signal.25,26
 binding domain. Tumor blood vessels mice treated                    SEMA3A inhibits EC adhesion, ­ migration sprouting.27,28
                                                                                  Semaphorins inhibit tumor growth, tumor angiogenesis  anti‑VEGF anti‑NRP1 demonstrated low pericyte association
                                                                                  metastasis. Overexpression SEMA3F ­ melanoma cells vivo
 tumor EC. pericytes stabilize tumor vessels, lack                                                                                   inhibited tumor angiogenesis metastasis.29 Interestingly,  pericytes suggests tumor blood vessels fragile                                                                                   appeared SEMA3F acted repelling EC preventing
 susceptible anti‑angiogenesis therapy. Anti‑NRP ­ inhibited              invasion tumor blood vessels. mechanism mimics
 vascular remodeling mouse‑developing retina.  anti‑NRP1              characterized SEMA repulsion axons. SEMA3B  antibodies prevent tumor vessel maturation  way,               appears inhibitor tumor progression. Adenocarcinoma
 vessels dependent VEGF   ­ susceptible                  cells ­transfected SEMA3B tumorigenic compared  anti‑VEGF treatment.                                                             controls.30 mechanism involves p53, tumor suppressor.
                                                                                  p53 increases levels SEMA3F,31 turn ­considered
Neuropilins Angiogenesis                                                      tumor suppressor.32 p53 knockdowns enhanced tumor
                                                                                  angiogenesis concomitant lower SEMA3F NRP2 gene
    evidence NRPs mediate angiogenesis,                     expression.31 noted SEMA3E exception normal pathological? NRPs expressed vascular                       rule. contrast class‑3 SEMAs, SEMA3E directly degree vessel type specificity, mouse,                 binds Plexin‑D1; SEMA3E‑plexin D1 ­ interactions required
chick, zebrafish embryo. NRP1 expressed arterial EC                     patterning intersomitic blood vessels (ISV) NRP2 expressed vein lymphatic EC.15‑18 Mouse                    NRP‑independent way.33 contrast SEMAs activity
knockout studies invaluable determining role                  suppressed furin‑dependent proteolysis,34 SEMA3E NRPs blood vessel development. number animal models                       activated cleavage turn promotes lung ­metastasis.35 used ­ delineate NRP function angiogenesis.                       Importantly, SEMA3A VEGF165 competitive inhibitors. indication NRP1 involved angiogenesis                   VEGF­165­ inhibits SEMA3A‑induced dorsal root ganglia (DRG)
demonstration overexpression Nrp1 transgenic mice                  collapse, SEMA3A inhibits VEGF165‑induced EC motility.28


www.landesbioscience.com	                                      Cell Adhesion & Migration	                                                            57
                                                                  Neuropilins Angiogenesis


                                                                                                            survival (Table 1). glioma,                                                                                                             increased NRP1 expression                                                                                                             concomitant increase VEGF VEGF
                                                                                                            receptors reported.42 patients
                                                                                                            poorer prognosis                                                                                                             NRP1 ­overexpression. Patients newly
                                                                                                            ­diagnosed untreated acute myeloid leukemia
                                                                                                             (AML) ­ demonstrated significant increase
                                                                                                             NRP1 ­ expression significantly
                                                                                                             poorer 5‑year overall survival compared
                                                                                                             controls.43 Patients advanced
                                                                                                             colorectal ­ carcinoma high levels                                                                                                              NRP1 staining showed significantly higher
                                                                                                             incidences lymph node liver metas-
                                                                                                             tasis shorter survival patients
 Figure 2.   Schematic view VEGF exon organization. Amino acid residues encoded exons
                                                                                                             low levels NRP.44 gastrointes-
 3 4, respectively, responsible interaction VEGFR‑1 VEGFR‑2, respectively. Exons
 6 7 represent VEGF heparan sulphate proteoglycan (HSPG) binding domains. Exons 7 8             tinal cancers NRP1 ­ expression correlated
 involved NRP binding. asterisks represent major targets therapeutics, (VEGFR‑2       increased invasive growth.45 NRP2
 NRP). (B) Strategies inhibit VEGF165 signaling VEGFR‑2. include VEGFR‑2 kinase expression ­ correlate tumor
 inhibitors (e.g., PTK787), soluble VEGFRs (e.g., VEGF‑trap), antibodies VEGFR‑2 (e.g., DC101)      progression. example, ­ osteosarcomas
 antibodies VEGF (Bevacizumab, Ranibizumab). (C) Strategies target VEGF165 interaction
                                                                                                            NRP2 expression showed ­significantly
 neuropilins. include: anti‑NRP1 antibodies, soluble NRP isoforms semaphorins (e.g.,                                                    46
 SEMA3A, SEMA3B, SEMA3F). addition, number peptide‑mimetics VEGF165 exons increased vascularity poorer ­prognosis.
 7/8 block interaction NRPs VEGF165 (137‑160), A7R, EG3287, Tuftsin              Expression NRP1 NRP2  analog TKPPR  Table 2).                                                                                significantly higher ovarian carcinomas
                                                                                                            benign tumors. Interestingly, SEMA structural basis competitiveness SEMAs strongly expressed benign tumors expressed VEGF165 bind NRP1/NRP2 B domain suggesting late stage ­carcinomas.36 Patients high VEGF SEMA ratio binding sites common.  ratio showed poorer survival low VEGF/SEMA ratios.
VEGF165 SEMA tip balance promoting expression NRP1 NRP2 ­nonsmall cell lung ­carcinomas
blocking angiogenesis. evidence possibility high (NSCLC) higher compared expression extraneoplastic
VEGF165/SEMA ratio correlated poor prognosis tissue.47  patients coexpression NRPs
ovarian carcinoma patients.36                                                   showed poorer prognosis increased vessel counts compared                                                                                 ­individuals ­ coexpression. ­ nonsmall cell lung ­ carcinoma,
Neuropilins Tumors                                                           levels NRP1 NRP2 increased different stages                                                                                  lung cancer, progressing dysplasia microinvasive carcinoma.48
    NRP1‑driven angiogenesis contributes tumor growth VEGF elevated SEMA3F levels remained low, mice. example, inducible overexpression NRP1 ­ prostate showing inverse relationship VEGF SEMA expression
­carcinoma cells vivo resulted larger highly vascular tumors.37 cancer. studies appear strong evidence  Tumor sections high levels VEGF165 protein, suggesting NRP expression elevated tumors, contrary report
 VEGF165 retained tumor binding NRP1. ­indicating expression NRP1 contributes better prognosis
 Similarly, human colon adenocarcinoma cells overexpressing NRP1 colon cancer.49 Gene expression levels NRP1 tumor  led larger angiogenic tumors compared controls.38 decreased compared extra‑neoplastic tissue levels.  Overexpression NRP1 U87MG human ­ glioblastoma, hand, NRP2 expression diminished tumors.
 expresses relative low levels receptor, resulted accelerated
 tumor growth angiogenesis compared control tumors.39  different note, overexpression NRP1 pancreatic cancer cells
                                                                                 Neuropilin Antagonists
 renders cells susceptible detachment‑induced apoptosis               Antagonists VEGF‑VEGF receptor interactions shown
 (anoikis) resistant chemotherapy (gemcitabine promise inhibitors tumor angiogenesis. antagonists
 5‑fluorouracil).40  opposite results pancreatic cancer include anti‑VEGF antibodies (Bevacizumab Ranimizumab,
 obtained Gray et al.41 study, overexpression NRP1 led Genentech),50 anti‑VEGFR‑2 antibody (DC101),51 VEGR kinase
 decreased tumorigenity pancreatic cancer line  contrast, inhibitors (e.g., PTK787)52 soluble VEGFRs, VEGF‑trap,
 NRP1 silencing significantly increased tumorigenity.                            soluble receptor consisting second Ig domain VEGFR‑1
                                                                                 fused Ig domain VEGFR‑2 (Fig. 2B).53
 Neuropilin Expression Cancer Patients                                           efficacy anti‑NRP1 antibody inhibitor tumor growth
                                                                                 preclinical tumor model4 suggests ­ worthwhile
    Clinical samples derived cancer patients demonstrated develop strategies inhibiting NRP activity. number
 different varieties tumors, NRP expression elevated NRP antagonists reported. ­ antagonists include
 enhancement correlated poor prognosis anti‑NRP1 antibodies (described , ­ semaphorins (described


58	                                                          Cell Adhesion & Migration	                                           2007; Vol. 1 Issue 2
                                                                                           Neuropilins Angiogenesis


Table 1	         Correlation neuropilin expression tumor progression

Tumor Type	NRP1	NRP2	Status	Reference
Glioma	                                                      h	            n 1	          Poorer prognosis	                                                                                            42
Acute myeloid leukemia	                                      h	            n 	           Poorer survival	                                                                                             43
Colon cancer	                                                h	            n 	           Poorer survival, higher lymph node liver metastasis	                                                     44
Gastrointestinal cancer	                                     h	            n 	           Higher invasiveness	                                                                                         45
Osteosarcoma	                                               n 	            h	            Increased vascularity, poorer prognosis	                                                                     46
Ovarian carcinoma	                                           h	              h	            Poorer prognosis; high VEGF/SEMA ratio prognostic poor survival	                                      36
Nonsmall cell lung carcinoma (NSCLC)	                        h	              h	            Poorer prognosis; increased vascularity	                                                                     47
Nonsmall cell lung carcinoma (NSCLC)	                        h	              h	            NRP1, NRP2, VEGF165 increase tumor stage; loss 	                                                    48
			                                                                                        SEMA3F premalignant lesions	
Colon cancer	                                                            n.c.2	          Poorer prognosis	                                                                                            49

n 1: analyzed; n.c.2: change.


Table 2	         Anti‑neuropilin strategies

Factor	                                   Mechanism	Reference
Semaphorins	                              Competition VEGF165 binding NRPs; Repulsion EC (SEMA3F)	                                                                                         28; 29
Anti‑NRP antibody	                        Inhibition VEGF165 binding length NRP; Additive effect anti‑VEGF tumor growth inhibition	                                                   4
Soluble NRP	������������������
                     Inhibition VEGF165 signaling; antitumor activity	                                                                                                                            55; 56
NRP B domain	                             Inhibition VEGF165 binding length NRP	                                                                                                              8
VEGF165 (137‑160)1	                       Inhibition VEGF‑induced EC proliferation	                                                                                                                  58
ATWLLPR (A7R)2	                           Inhibition VEGF165 binding NRP; Antiangiogenic antitumor activity	                                                                                  61
EG32873	                                  Inhibition VEGFR‑2 phosphorylation downstream signaling	                                                                                               59
TKPPR4	                                   Inhibition VEGFR‑2 activation	                                                                                                                             60
1VEGF    fragment consisting exon 7 (amino acids 22–44) amino acid exon 8, cysteine residue; 2Peptide identified screening mutated phage library anti‑VEGF antibody blocks
     165
VEGF165‑dependent EC proliferation; 3Byciclic peptide consisting exon 7 (amino acids 23–4) exon 8; 4Tuftsin‑like peptide (TKPR). Homologous VEGF165 exon 8.

 , soluble NRP1 (sNRP1), peptides derived VEGF165                                             desirable inhibit VEGF activity semaphorins, NRPs block VEGF­165‑NRP ­interactions (Fig. 2C                                            ­angiogenesis ­inhibitors.
Table 2).                                                                                                       Strategies developed target VEGF‑NRP1 ­interaction
     Naturally occurring sNRPs originate alternative splicing                                        based interfering VEGF exons 7 8 binding NRP1. NRP gene introns yielding spliced isoforms.54,55                                          example, peptide corresponding VEGF exon 7 (44 amino protein level sNRPs consist extracellular NRP domains,                                         acids) 8 (6 amino acids) inhibited VEGF165 binding NRP1 particular B subdomains.54‑56 Overexpression sNRP1                                           VEGF165‑induced EC proliferation.58 active region prostate cancer cells resulted tumors severely ­apoptotic                                    second half exons 7, amino acids 22–44 contained mainly damaged hemorrhagic tumor vessels,                                                  plus amino acid exon 8, cysteine residue. bicyclic
ostensibly inhibiting VEGF function.55  sNRP1                                                 peptide, EG3287, based NRP1 binding site located VEGF
acting VEGF trap. Similarly, sNRP1 inhibited human breast                                               exons 7 8, inhibited VEGF165 binding PAE‑NRP1 cells
carcinoma cell migration mechanism implying sequestering                                             PAE cells expressing VEGF receptor tyrosine kinases
endogenous VEGF165.56 Taken  data suggest NRP                                            (VEGFR‑1 VEGFR‑2).59 bicyclic peptide,  did
soluble isoforms act VEGF165 antagonists sequester                                             inhibit cross‑linking VEGF165 VEGFR‑2 ECs coexpressing
VEGF165 prevent tumorigenic angiogenic effects                                                   VEGFR‑2 NRP1, result inhibited VEGF165 signaling,
­mediated length NRP.                                                                            e.g., VEGFR‑2, PLC‑g ERK phosphorylation.59 importance
     VEGF165 exons 7/8 binds solely NRP B domain                                              VEGF exon 8 NRP binding substantiated  (Geretti E Klagsbrun M, unpublished).8,9,57  NRP B                                               study showing Tuftsin (TKPR), analogue VEGF exon 8
 domain peptide potential competitive inhibitor VEGF‑NRP                                             (CDKPRR), inhibited VEGF165 binding NRP1.60 analogous
 ­interactions. advantage NRP B domain peptide                                            synthetic peptide, TKPPR, higher affinity antagonist.
  targets VEGF165  SEMAs, require                                        TKPPR inhibited VEGF165‑induced VEGFR‑2 activation   B domains optimal interaction receptor (Geretti E                                       directly inhibiting VEGF165 binding VEGFR‑2. peptide,
  Klagsbrun M, unpublished).9,10 selectivity                                               ATWLLPR (A7R), inhibited VEGF165 binding NRP1   ­important vivo anti‑angiogenesis applications                                       VEGFR‑2. A7R inhibited EC proliferation, tube formation 

www.landesbioscience.com	                                                            Cell Adhesion & Migration	                                                                                                 59
                                                                                    Neuropilins Angiogenesis


growth MDA‑MB231 mouse xenografts.61 Taken                                          	 6.	  Tessier‑Lavigne M. Neuropilin receptor axonal chemorepellent
                                                                                                          Semaphorin III. Cell 1997; 90:739‑51.
appears class VEGF165 inhibitors developed                                 	 7.	 Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin‑1 expressed consists rationally designed peptides purpose blocking                                      endothelial tumor cells isoform‑specific receptor vascular endothelial growth
VEGF‑NRP interactions.                                                                                    factor. Cell 1998; 92:735‑45.
                                                                                                   	 8.	 Mamluk R, Gechtman  Kutcher  Gasiunas N, Gallagher J, Klagsbrun M.
                                                                                                          Neuropilin‑1 binds vascular endothelial growth factor 165, placenta growth factor‑2, Future Directions NRP Research                                                                        heparin b1b2 domain. J Biol Chem 2002; 277:24818‑25.
                                                                                                   	 9.	 Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, Ginty DD,
        solid evidence NRPs mediate tumor progression,                                      Kolodkin AL. Characterization neuropilin‑1 structural features confer bind-
                                                                                                          ing semaphorin 3A vascular endothelial growth factor 165. J Biol Chem 2002; stimulators VEGF‑mediated pathways inhibitors                                          277:18069‑76. SEMA‑mediated pathways. areas research prove                                   	 10.	 Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin‑1 extracel- beneficial. develop NRP ­ antagonists                                          lular domains mediate semaphorin D/III‑induced growth cone collapse. Neuron 1998; rational manner. example, anti‑NRP1 antibody                                                 21:1093‑100.
                                                                                                   	 11.	 Wang L, Mukhopadhyay D, Xu X. C terminus RGS‑GAIP‑interacting protein conveys
proven effective inhibiting tumor growth combination                                          neuropilin‑1‑mediated signaling angiogenesis. Faseb J 2006; 20:1513‑5. anti‑VEGF antibody. anti‑NRP2 antibody prove                                         	 12.	 Cai H, Reed RR. Cloning characterization neuropilin‑1‑interacting protein: useful curbing tumor progression combination                                             PSD‑95/Dlg/ZO‑1 domain‑containing protein interacts cytoplasmic domain
                                                                                                          neuropilin‑1. J Neurosci 1999; 19:6519‑27.
anti‑NRP1 antibody. anti‑NRP2 antibody useful                                                                                                    	 13.	 Gao Y, Li M, Chen W, Simons M. Synectin, syndecan‑4 cytoplasmic domain binding PDZ
inhibiting ­lymphangiogenesis tumors lymphatic EC express                                        protein, inhibits cell migration. J Cell Physiol 2000; 184:373‑9.
solely NRP2.                                                                                       	 14.	 Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein 
                                                                                                          Ruiz Almodovar C, Dedkov E, Tomanek R, Li W, Westmore M, Singh JP, Horowitz 
        antibody approach, strategy                                     Mulligan‑Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M. Selective regulation
­developed holds promise target VEGF exon 7 ­interactions                                       arterial branching morphogenesis synectin. Dev Cell 2006; 10:783‑95.
 NRP B domain. NRP soluble fragments VEGF exons                                       	 15.	 Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G. Differential expression neuro-
                                                                                                          pilin‑1 neuropilin‑2 arteries veins. Mech Dev 2001; 109:115‑9.
 7/8 mimetics described studies                               	 16.	 Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, Eichmann 
 expanded. availability B domain crystal structures,                                        Abnormal lymphatic vessel development neuropilin 2 mutant mice. Development 2002;
 example, b1 domain NRP162 B domain NRP1,                                               129:4797‑806.
                                                                                                   	 17.	 Eichmann  Yuan L, Moyon D, Lenoble F, Pardanaud L, Breant C. Vascular develop-
 cocrystallized Tuftsin,63 offer valuable starting points rational                               ment: precursor cells branched arterial venous networks. Int J Dev Biol 2005;
 structure-based inhibitor design. example, ­ mutations B                                      49:259‑67.
 domain bind VEGF tightly efficient                                    	 18.	 Yaniv K, Isogai S, Castranova D, Dye L, Hitomi J, Weinstein BM. Live imaging lym-
                                                                                                          phatic development zebrafish. Nat Med 2006; 12:711‑6.
 sequestering VEGF (Geretti E Klagsbrun M, unpublished).                                    	 19.	 Kitsukawa T, Shimono  Kawakami  Kondoh H, Fujisawa H. Overexpression mem-
 strategies, important affect adversely                                   brane protein, neuropilin, chimeric mice causes anomalies cardiovascular 
 SEMA binding NRPs SEMAs inhibitors tumor                                            nervous limbs. Development 1995; 121:4309‑18.
                                                                                                   	 20.	 Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H. requirement
 progression.                                                                                             neuropilin‑1 embryonic vessel formation. Development 1999; 126:4895‑902.
        important aspect NRP relationship tumors                               	 21.	 Chen H, Bagri  Zupicich JA, Zou Y, Stoeckli E, Pleasure SJ, Lowenstein DH, Skarnes
 expand analysis NRPs expression VEGF                                             WC, Chedotal  Tessier‑Lavigne M. Neuropilin‑2 regulates development selec-
                                                                                                          tive cranial sensory nerves hippocampal mossy fiber projections. Neuron 2000;
 SEMAs levels patients. far, seven                                  25:43‑56.
 tumor types increase NRP1, NRP2 NRP levels.                                    	 22.	 Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Miyazaki
                                                                                                          Ji J, Hirota S, Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M, Hori M. Targeting  larger sampling patient data critical ­ ascertaining                                    mouse neuropilin‑1 neuropilin‑2 genes severely impairs developmental yolk sac  ­reliability. work based immunohistological                                           embryonic angiogenesis. Proc Natl Acad Sci USA 2002; 99:3657‑62.
  ­analysis tumor sections beneficial develop                                	 23.	 Lee P, Goishi K, Davidson AJ, Mannix R, Zon L, Klagsbrun M. Neuropilin‑1 required
                                                                                                          vascular development mediator VEGF‑dependent angiogenesis zebrafish.
   quantitative analytical methods (e.g., ELISA) purpose.                                   Proc Natl Acad Sci USA 2002; 99:10470‑5.
   interesting possibility VEGF/SEMA ratios                                	 24.	 Kolodkin AL, Levengood DV, Rowe  Tai YT, Giger RJ, Ginty DD. Neuropilin    ­diagnostic. Finding ways upregulating endogenous SEMAs (3A,                                        semaphorin III receptor. Cell 1997; 90:753‑62.
                                                                                                   	 25.	 Nakamura F, Kalb RG, Strittmatter SM. Molecular basis semaphorin‑mediated axon
    3B 3F) counteract VEGF activity.                                                            guidance. J Neurobiol 2000; 44:219‑29.
        summary, NRPs mediate stimulation (VEGF)                                 	 26.	 Tamagnone L, Comoglio PM. Signalling semaphorin receptors: Cell guidance     inhibition (SEMA) tumor angiogenesis progression.                                        Trends Cell Biol 2000; 10:377‑83.
                                                                                                   	 27.	 Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L,
    Inhibiting VEGF‑NRP interactions promoting SEMA‑NRP                                             Primo L, Tamagnone L, Logan M, Tessier‑Lavigne M, Taniguchi M, Puschel AW, Bussolino
    interactions rational approaches regulating tumor                                         F. Class 3 semaphorins control vascular morphogenesis inhibiting integrin function.
    ­angiogenesis progression.                                                                        Nature 2003; 424:391‑7.
                                                                                                   	 28.	 Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin‑1 mediates
    References                                                                                            collapsin‑1/semaphorin III inhibition endothelial cell motility: Functional competition
	 1.	 Ferrara N, Kerbel RS. Angiogenesis therapeutic target. Nature 2005; 438:967‑74.                collapsin‑1 vascular endothelial growth factor‑165. J Cell Biol 1999; 146:233‑42.
	 2.	 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY.                     	 29.	 Bielenberg DR, Hida Y, Shimizu  Kaipainen  Kreuter M, Kim CC, Klagsbrun M.
      Ranibizumab neovascular age‑related macular degeneration. N Engl J Med 2006;                    Semaphorin 3F, chemorepulsant endothelial cells, induces poorly vascularized, encap-
                                                                                                          sulated, nonmetastatic tumor phenotype. J Clin Invest 2004; 114:1260‑71.
      355:1419‑31.
                                                                                                   	 30.	 Tse C, Xiang RH, Bracht T, Naylor SL. Human Semaphorin 3B (SEMA3B) located 	 3.	 Hurwitz H, Saini S. Bevacizumab treatment metastatic colorectal cancer: Safety
                                                                                                          chromosome 3p21.3 suppresses tumor formation adenocarcinoma cell line. Cancer
      profile management adverse events. Semin Oncol 2006; 33:S26‑34.
                                                                                                          Res 2002; 62:542‑6.
	 4.	 Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee         	 31.	 Futamura M, Kamino H, Miyamoto Y, Kitamura N, Nakamura Y, Ohnishi S, Masuda Y,
      SF, Pacheco G, Ross S, Cheng  Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri               Arakawa H. Possible role semaphorin 3F, candidate tumor suppressor gene 3p21.3,
       Tessier‑Lavigne M, Watts RJ. Blocking neuropilin‑1 function additive effect          p53‑regulated tumor angiogenesis suppression. Cancer Res 2007; 67:1451‑60.
      anti‑VEGF inhibit tumor growth. Cancer Cell 2007; 11:53‑67.                               	 32.	 Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI,
	 5.	 Takagi S, Tsuji T, Amagai T, Takamatsu T, Fujisawa H. Specific cell surface labels           Minna JD. Human semaphorins V) IV reside 3p21.3 small cell lung cancer
      visual centers Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol           deletion region demonstrate distinct expression patterns. Proc Natl Acad Sci USA 1996;
      1987; 122:90‑100.                                                                                   93:4120‑5.


60	                                                                           Cell Adhesion & Migration	                                                                2007; Vol. 1 Issue 2
                                                                                       Neuropilins Angiogenesis


	 33.	 Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, Henderson CE, Jessell TM,                	 55.	 Gagnon ML, Bielenberg DR, Gechtman  Miao HQ, Takashima S, Soker S, Klagsbrun M.
       Kolodkin AL, Ginty DD. Semaphorin 3E plexin‑D1 control vascular pattern indepen-                   Identification natural soluble neuropilin‑1 binds vascular endothelial growth factor:
       dently neuropilins. Science 2005; 307:265‑8.                                                        vivo expression antitumor activity. Proc Natl Acad Sci USA 2000; 97:2573‑8.
	 34.	 Adams RH, Lohrum M, Klostermann  Betz H, Puschel AW. chemorepulsive activity              	 56.	 Cackowski FC, Xu L, Hu B, Cheng SY. Identification novel alternatively spliced
       secreted semaphorins regulated furin‑dependent proteolytic processing. Embo J                 Neuropilin‑1 isoforms. Genomics 2004; 84:82‑94.
       1997; 16:6077‑86.                                                                               	 57.	 Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L,
	 35.	 Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L,                         Alitalo K. Functional interaction VEGF‑C VEGF‑D neuropilin receptors. Faseb
       Guldberg P, Lukanidin E. Proteolytic processing converts repelling signal Sema3E              J 2006; 20:1462‑72.
       inducer invasive growth lung metastasis. Cancer Res 2005; 65:6167‑77.                 	 58.	 Soker S, Gollamudi‑Payne S, Fidder H, Charmahelli H, Klagsbrun M. Inhibition 	 36.	 Osada R, Horiuchi  Kikuchi N, Ohira S, Ota M, Katsuyama Y, Konishi  Expression                     vascular endothelial growth factor (VEGF)‑induced endothelial cell proliferation        semaphorins, vascular endothelial growth factor, common receptor neuropil-                peptide corresponding exon 7‑encoded domain VEGF165. J Biol Chem 1997;
       ins alleic loss semaphorin locus epithelial ovarian neoplasms: Increased ratio            272:31582‑8.
       vascular endothelial growth factor semaphorin poor prognostic factor ovarian         	 59.	 Jia H, Bagherzadeh  Hartzoulakis B, Jarvis  Lohr M, Shaikh S, Aqil R, Cheng L, Tickner
       carcinomas. Hum Pathol 2006; 37:1414‑25.                                                               M, Esposito D, Harris R, Driscoll PC, Selwood DL, Zachary IC. Characterization 	 37.	 Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin‑1 expression tumor cells                    bicyclic peptide neuropilin‑1 (NP‑1) antagonist (EG3287) reveals importance vascular
       promotes tumor angiogenesis progression. Faseb J 2000; 14:2532‑9.                                  endothelial growth factor exon 8 NP‑1 binding role NP‑1 KDR signaling. J
	 38.	 Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, Reinmuth N, Bielenberg D, Bucana                     Biol Chem 2006; 281:13493‑502.
       CD, Klagsbrun M, Ellis LM. Neuropilin‑1 human colon cancer: Expression, regulation,          	 60.	 von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, Ramalingam
       role induction angiogenesis. J Pathol 2004; 164:2139‑51.                                  K, Arunachalam T, Eaton S, Linder KE, Yan F, Pochon S, Tweedle MF, Nunn AD. Tuftsin
	 39.	 Hu B, Guo P, Bar‑Joseph  Imanishi Y, Jarzynka MJ, Bogler O, Mikkelsen T, Hirose T,                   binds neuropilin‑1 sequence similar encoded exon 8 vascular endo-
       Nishikawa R, Cheng SY. Neuropilin‑1 promotes human glioma progression poten-                   thelial growth factor. J Biol Chem 2006; 281:5702‑10.
       tiating activity HGF/SF autocrine pathway. Oncogene 2007.                            	 61.	 Starzec  Vassy R, Martin  Lecouvey M, Di Be